Benzinga - by Benzinga Insights, Benzinga Staff Writer.
A substantial insider activity was disclosed on December 7, as Silvernail, Board Member at Stryker (NYSE:SYK), reported the exercise of a large sell of company stock options.
What Happened: Silvernail, Board Member at Stryker, exercised stock options for 4,355 shares of SYK stock. This information was disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday. The exercise price of the options was $81.14 per share.
The Friday morning update indicates Stryker shares down by 0.5%, currently priced at $287.94. At this value, Silvernail's 4,355 shares are worth $900,635.
Unveiling the Story Behind Stryker Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
Stryker: A Financial Overview Revenue Growth: Over the 3 months period, Stryker showcased positive performance, achieving a revenue growth rate of 9.6% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics:
- Gross Margin: The company sets a benchmark with a high gross margin of 64.33%, reflecting superior cost management and profitability compared to its peers.
- Earnings per Share (EPS): Stryker's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 1.82.
Understanding Financial Valuation:
- Price to Earnings (P/E) Ratio: Stryker's P/E ratio of 42.93 is below the industry average, suggesting the stock may be undervalued.
- Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 5.58, Stryker's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
- EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 25.82, Stryker presents an attractive value opportunity.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Uncovering the Importance of Insider Activity Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down.
The Insider's Guide to Important Transaction Codes When analyzing transactions, investors tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Stryker's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.